In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has issued a complete response letter rejecting ITM's radiopharmaceutical therapy ITM-11, a drug positioned to compete with Novartis treatments.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The FDA issued a Complete Response Letter rejecting ITM's radiopharmaceutical drug, 177Lu-edotreotide (ITM-11), for the treatment of GEP-NETs. Coverage indicated that the surprise decision was driven by manufacturing problems and qualifications.
Epilogue added 96d ago, after coverage quieted.
The brief
Food and Drug Administration has issued a complete response letter to ITM regarding the New Drug Application for 177Lu-edotreotide, also known as ITM-11. This regulatory action constitutes a rejection of the radiopharmaceutical therapy. The decision prevents the drug from moving forward toward market approval in its current state, marking a significant setback for the development timeline of this specific cancer treatment. Coverage from Fierce Pharma emphasizes that the FDA's decision was driven by concerns over manufacturing. Specifically, the agency spurned the drug due to manufacturing qualms, indicating that the production processes did not meet the necessary regulatory standards for approval.
STAT describes the ruling as a surprise decision, highlighting the unexpected nature of the rejection given the anticipated trajectory of the drug's approval process. These outlets collectively underscore a gap between the clinical expectations and the operational realities of the drug's manufacturing scale. Contextual reports from STAT indicate that ITM-11 was widely expected to serve as a rival to an existing treatment provided by Novartis. The radiopharma sector is characterized by high competition and complex delivery mechanisms, making the failure to satisfy manufacturing requirements a critical blow. Because the therapy was positioned as a direct competitor to a Novartis product, the FDA's rejection maintains the current market status quo and delays the entry of a potential alternative for patients requiring this type of radiopharmaceutical intervention.
Moving forward, the focus remains on how ITM will respond to the complete response letter. While the coverage does not specify the exact nature of the manufacturing flaws, the company must now address the FDA's stated qualms to seek future approval. Observers will be watching for official statements from ITM regarding their plan to rectify the production issues or whether they will provide further data to the agency. The immediate impact is a halt in the commercialization of 177Lu-edotreotide until the regulatory hurdles identified by the FDA are fully resolved.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (93% supported) Updated 99d ago.
Quick answers
What is ITM-11?
ITM-11, also known as 177Lu-edotreotide, is a radiopharmaceutical cancer therapy.
Why did the FDA reject the drug?
According to Fierce Pharma, the FDA rejected the drug due to concerns regarding manufacturing.
Which company was ITM-11 expected to compete with?
STAT reports that the therapy was expected to rival a treatment from Novartis.
Coverage (7)
- Manufacturing problems cited in FDA rejection of ITM's radiopharma drug Endpoints News · 99d ago
- ITM receives Complete Response Letter for ITM-11 AuntMinnie · 99d ago
- 177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment CancerNetwork · 99d ago
- ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11) WBOC TV · 99d ago
- ITM Says FDA Issues Complete Response Letter For 177Lu-Edotreotide (ITM-11) NDA TradingView · 99d ago
- ITM cancer drug spurned by FDA over manufacturing qualms Fierce Pharma · 99d ago
- In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment STAT · 99d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.